These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2302378)

  • 61. In-vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced?
    Metterlein T; Schuster F; Kranke P; Roewer N; Anetseder M
    Eur J Anaesthesiol; 2011 Apr; 28(4):251-5. PubMed ID: 20827211
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.
    Larach MG
    Anesth Analg; 1989 Oct; 69(4):511-5. PubMed ID: 2675676
    [No Abstract]   [Full Text] [Related]  

  • 63. Evaluation of greyhound susceptibility to malignant hyperthermia using halothane-succinylcholine anesthesia and caffeine-halothane muscle contractures.
    Cosgrove SB; Eisele PH; Martucci RW; Gronert GA
    Lab Anim Sci; 1992 Oct; 42(5):482-5. PubMed ID: 1460848
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of halothane on mechanical response of skeletal muscle from malignant hyperthermia susceptible patients.
    Etchrivi TS; Adnet PJ; Tavernier B; Diallo A; Haudecoeur G; Krivosic-Horber RM
    Arch Physiol Biochem; 1998 Oct; 106(4):318-24. PubMed ID: 10417859
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Laboratory diagnosis of malignant hyperpyrexia susceptibility (MHS). European MH Group.
    Br J Anaesth; 1985 Oct; 57(10):1038. PubMed ID: 4041311
    [No Abstract]   [Full Text] [Related]  

  • 66. The importance of calcium ions for in vitro malignant hyperthermia testing.
    Fletcher JE; Huggins FJ; Rosenberg H
    Can J Anaesth; 1990 Sep; 37(6):695-8. PubMed ID: 2208545
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Malignant hyperthermia susceptibility in a patient with mitochondrial disorder.
    Finsterer J; Michalek-Sauberer A; Höftberger R
    Metab Brain Dis; 2009 Sep; 24(3):501-6. PubMed ID: 19714456
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy.
    Payen JF; Bosson JL; Bourdon L; Jacquot C; Le Bas JF; Stieglitz P; Benabid AL
    Anesthesiology; 1993 May; 78(5):848-55. PubMed ID: 8489056
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [A new emphasis on the diagnosis of malignant hyperthermia using the in vitro contracture test?].
    Olthoff D; Meinecke CD
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1991 Dec; 26(8):454-8. PubMed ID: 1786305
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
    Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
    Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Malignant hyperthermia in humans--standardization of contracture testing protocol.
    Melton AT; Martucci RW; Kien ND; Gronert GA
    Anesth Analg; 1989 Oct; 69(4):437-43. PubMed ID: 2782643
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [In vitro diagnosis of malignant hyperpyrexia syndrome].
    Eldar I; Goldberg G; Glauber V; Perel A
    Harefuah; 1991 Dec; 121(12):499-502. PubMed ID: 1794753
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Xenon does not induce contracture in human malignant hyperthermia muscle.
    Baur CP; Klingler W; Jurkat-Rott K; Froeba G; Schoch E; Marx T; Georgieff M; Lehmann-Horn F
    Br J Anaesth; 2000 Nov; 85(5):712-6. PubMed ID: 11094586
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Malignant hyperthermia susceptibility in 3 patients with malignant neuroleptic syndrome].
    Silva HC; Bahia VS; Oliveira RA; Marchiori PE; Scaff M; Tsanaclis AM
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):713-9. PubMed ID: 10973114
    [TBL] [Abstract][Full Text] [Related]  

  • 75. 3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility.
    Lacava C; Michalek-Sauberer A; Kraft B; Sgaragli G; Sipos E; Höller C; Kress HG; Fusi F; Weigl LG
    Pharmacol Res; 2012 Jul; 66(1):80-7. PubMed ID: 22480578
    [TBL] [Abstract][Full Text] [Related]  

  • 76. An evaluation of procaine in the treatment of malignant hyperpyrexia.
    Clarke IM; Ellis FR
    Br J Anaesth; 1975 Jan; 47(1):17-21. PubMed ID: 1148070
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [The action of ketamine on muscle contractile behavior. In vitro studies on the musculature of subjects susceptible to malignant hyperthermia].
    Hackl W; Winkler M; Mauritz W; Steinbereithner K
    Anaesthesist; 1989 Dec; 38(12):681-5. PubMed ID: 2619030
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cytosolic free calcium concentrations in lymphocytes from malignant hyperthermia susceptible patients.
    Ording H; Foder B; Scharff O
    Br J Anaesth; 1990 Mar; 64(3):341-5. PubMed ID: 2328183
    [TBL] [Abstract][Full Text] [Related]  

  • 79. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil].
    Almeida da Silva HC; Ferreira G; Rodrigues G; Santos JMD; Andrade PV; Hortense A; Vaz Perez M; Amaral JLGD
    Braz J Anesthesiol; 2019; 69(2):152-159. PubMed ID: 30935497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.